To address this gap, we performed a systematic review and meta-analysis of observational studies to evaluate the potential effectiveness on cardiorenal endpoints and the safety of combining an SGLT2 inhibitor with a GLP-1 RA compared with SGLT2 inhibitor or GLP-1 RA monotherapy in individuals with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.